Immunotherapy developer Immune Design said it will halt a Phase III trial for its lead pipeline candidate, the cancer vaccine CMB305, following disappointing Phase II results in synovial sarcoma, and will instead accelerate and expand development of its next-furthest along candidate, the intratumoral TLR4 agonist G100. Immune Design said it will “deprioritize” development of CMB305, a prime-boost cancer vaccine designed to target tumors that express the cellular protein NY-ESO-1, which is often frequently expressed in synovial sarcomas. The company and halt the Phase III SYNOVATE trial ( NCT03520959 ), which is designed to assess the cancer vaccine in patients with unresectable, locally-advanced or metastatic NY-ESO-1 positive synovial sarcoma following first-line systemic anti-cancer therapy. SYNOVATE had been recruiting patients toward a planned enrollment of 248 participants, as of the study’s most recent update August 24 on ClinicalTrials.gov. Yesterday Immune Design cited an early analysis of data from ...